These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 14962236)

  • 1. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
    Breems DA; Sonneveld P; de Man RA; Leebeek FW
    Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
    Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
    Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura.
    Patriarca F; Geromin A; Fanin R; Damiani D; Sperotto A; Baccarani M
    Bone Marrow Transplant; 1999 Aug; 24(4):433-5. PubMed ID: 10467336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of systemic amyloidosis treated by chemotherapy with autologous peripheral blood stem cell transplantation].
    Mito A; Daga H; Ohashi N; Akita S; Shiomi K; Arita K; Fujiwara M; Asaoku H
    Nihon Kokyuki Gakkai Zasshi; 2006 Aug; 44(8):583-8. PubMed ID: 16972617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
    Sezer O; Schmid P; Shweigert M; Heider U; Eucker J; Harder H; Sinha P; Radtke H; Possinger K
    Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy and autologous transplantation in amyloidosis-AL.
    Majolino I; Marcenò R; Pecoraro G; Scimé R; Vasta S; Liberti G; Rizzo A; Indovina A; Caronia F
    Haematologica; 1993; 78(1):68-71. PubMed ID: 8098314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
    Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
    Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation.
    Reich G; Held T; Siegert W; Kampf D; Dörken B; Maschmeyer G
    Bone Marrow Transplant; 2001 Feb; 27(3):341-3. PubMed ID: 11277185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
    Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
    Choufani EB; Sanchorawala V; Ernst T; Quillen K; Skinner M; Wright DG; Seldin DC
    Blood; 2001 Mar; 97(6):1885-7. PubMed ID: 11238135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
    Oran B; Malek K; Sanchorawala V; Wright DG; Quillen K; Finn KT; La Valley M; Skinner M; Seldin DC
    Bone Marrow Transplant; 2005 Mar; 35(6):567-75. PubMed ID: 15665842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AL amyloidosis manifesting as systemic lymphadenopathy.
    Matsuda M; Gono T; Shimojima Y; Yoshida T; Katoh N; Hoshii Y; Yamada T; Ikeda S
    Amyloid; 2008 Jun; 15(2):117-24. PubMed ID: 18484338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary amyloidosis associated to severe factor X deficiency].
    Pérez Martínez J; Llamas F; López Montes A; Massó P; Poblet E; López Rubio E; Gallego E; Gómez Roldán C
    Nefrologia; 2004; 24(5):493-8. PubMed ID: 15648909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.